• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Incyte Corp.

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    SC 13G 1 Incyte_Corp.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    INCYTE CORP

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    45337C102

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    45337C102 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,423,375

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    10,551,279

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,552,047.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.5%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    45337C102 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      INCYTE CORP

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      45337C102

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    45337C102 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 10,552,047.00  
      (b) Percent of class: 5.5%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 7,423,375
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 10,551,279
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ¨
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS (JAPAN) CO., LTD. (IA) STATE STREET GLOBAL ADVISORS ASIA LIMITED (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS SINGAPORE LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA) STATE STREET SAUDI ARABIA FINANCIAL SOLUTIONS COMPANY (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    45337C102 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $INCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    12/8/2025$121.00Neutral → Outperform
    Mizuho
    11/3/2025$125.00Neutral → Buy
    Guggenheim
    10/8/2025Outperform → Perform
    Oppenheimer
    8/6/2025$89.00Equal Weight → Overweight
    Wells Fargo
    8/1/2025$90.00Overweight
    Barclays
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Incyte upgraded by Mizuho with a new price target

    Mizuho upgraded Incyte from Neutral to Outperform and set a new price target of $121.00

    12/8/25 8:14:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Guggenheim with a new price target

    Guggenheim upgraded Incyte from Neutral to Buy and set a new price target of $125.00

    11/3/25 9:08:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte downgraded by Oppenheimer

    Oppenheimer downgraded Incyte from Outperform to Perform

    10/8/25 8:24:02 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    SEC Filings

    View All

    Incyte Corp. filed SEC Form 8-K: Leadership Update

    8-K - INCYTE CORP (0000879169) (Filer)

    12/12/25 11:34:47 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by Incyte Corp.

    144 - INCYTE CORP (0000879169) (Subject)

    11/21/25 4:17:23 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Incyte Corp.

    SCHEDULE 13G - INCYTE CORP (0000879169) (Subject)

    11/10/25 8:35:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Scientific Officer Mayes Patrick A sold $554,965 worth of shares (5,808 units at $95.55), decreasing direct ownership by 9% to 60,011 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/12/25 4:01:54 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Hoppenot Herve covered exercise/tax liability with 2,843 shares, decreasing direct ownership by 0.86% to 326,803 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/10/25 4:06:42 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Medical Officer Stein Steven H covered exercise/tax liability with 17,093 shares and sold $2,324,438 worth of shares (22,664 units at $102.56), decreasing direct ownership by 39% to 63,129 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/3/25 4:36:44 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incyte Announces Change to its Board of Directors

    Incyte (NASDAQ:INCY) today announced the resignation of Hervé Hoppenot from the Company's Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor to the Chief Executive Officer (CEO) and as a member of the Board during a planned transition period. Mr. Hoppenot joined Incyte in 2014 and previously served as Chairman and CEO. "On behalf of the Board of Directors, I would like to thank Hervé for his steadfast leadership, vision and guidance throughout his tenure, which helped grow Incyte into a leading, innovative company," said Julian Baker, Managing Partner of Baker Bros. Advisors LP and Incyte's Chairman of the Board. "Hervé leaves a

    12/12/25 8:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

    The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators Updated safety and efficacy data for INCA033989 in ET, and new data in myelofibrosis (MF), will be presented at the upcoming 2025 ASH Annual Meeting Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for the treatment of patients with essential thrombocythemia (ET) harboring a Type 1 CALR mutation who are resistant or intoler

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

    Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

    Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help

    12/1/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

    Incyte (NASDAQ:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company's strategy and business development. "Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development," said Bill Meury, President and Chief Executive Officer, Incyte. "Dave will play a pivotal role in developing a coherent and e

    9/22/25 7:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

    Incyte (NASDAQ:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company's global human resources strategy including talent acquisition, organizational design and professional development. "Soni has extensive knowledge and experience in all aspects of human resources," said Bill Meury, President and Chief Executive Officer, Incyte. "She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will pla

    8/25/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

    Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

    INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on

    11/3/25 9:31:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reported financial results for the t

    10/28/25 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care